DNAprint Genomics (DNAG)

[gunnabeoneday]

here's DNAG's claim contained within their latest WIPO patent application.

it is interesting that they state "marker" (singular) and link that to a snp from a group of many, many nucleotides. i wonder if 2 snps are discovered in the patient if they consider that 2 markers??

clearly more than just one area is being tested.



What is claimed is:

1. A method for inferring a muscle adverse effect statin response of a human subject from a nucleic acid sample of the subject, comprising identifying in the nucleic acid sample, an occurrence of at least one statin response-related single nucleotide polymorphism (SNP) of a marker, wherein the marker has a sequence selected from the group consisting of: a. nucleotides 3911-4379 of SEQ ID NO: 134; b. nucleotides 31264-31822 of SEQ ID NO: 131 ; c. nucleotides 22281-23778 of SEQ ID NO: 143; d. nucleotides 3482-4414 of SEQ ID NO: 134; e. nucleotides 1895-2286 of SEQ ID NO: 132; f. nucleotides 650-1166 of SEQ ID NO:131; g. nucleotides 771-1171 of SEQ ID NO: 142; h. nucleotides 79999-80360 of SEQ ID NO: 133; i. nucleotides 31264-31822of SEQ ID NO: 131; j. nucleotides 2440-2560 of SEQ ID NO: 134; k. nucleotides 23757-24069 of SEQ ID NO: 131 ; 1. nucleotides 30438-30711 of SEQ ID NO: 131; m. nucleotides 23571-24967 of SEQ ID NO: 131; n. nucleotides 12971-14510 of SEQ ID NO: 143; o. nucleotides 26896-27098 of SEQ ID NO: 130; p. nucleotides 8115-8737 of SEQ ID NO: 143; q . nucleotides 13465-13865 of SEQ ID NO:138; r. nucleotides 26056-26456 of SEQ ID NO: 138; s. nucleotides 26167-26197 of SEQ ID NO:138; t. nucleotides 17636-18035 of SEQ ID NO:138; u. nucleotides 25354-25754 of SEQ ID NO: 138; v. nucleotides 12153-12553 of SEQ ID NO:138; w. nucleotides 7082-7942 of SEQ ID NO: 139; x. nucleotides 5779-5827 of SEQ ID NO: 135; y. nucleotides 5851-6442 of SEQ ID NO:135; z. nucleotides 7909-8504 of SEQ ID NO: 139;

aa. nucleotides 651-1166 of SEQ ID NO:131; ab. nucleotides 4351-4750 of SEQ ID NO:139; ac. nucleotides 3138-3500 of SEQ ID NO:139; ad. nucleotides 3482-4414 of SEQ ID NO:131; ae. nucleotides 4397-4797 of SEQ ID NO: 139; af. nucleotides 31264-31813 of SEQ ID NO:131; ag. nucleotides 16240-16589 of SEQ ID NO:145; ah. nucleotides 25192-2298 of SEQ ID NO:145; ai. nucleotides 11344-12528 of SEQ ID NO: 139; aj. nucleotides 2800-3685 of SEQ ID NO:129; ak. nucleotides 30350-30631 of SEQ IDNO:131; al. nucleotides 750-1110 of SEQ ID NO:134; am. nucleotides 5880-6229 of SEQ ID NO: 145; an. nucleotides 25192-25479 of SEQ ID NO:145; ao. nucleotides 17794-18106 of SEQ ID NO:130; ap. nucleotides 26895-27098 of SEQ ID NO: 130; aq. nucleotides 26895-25478 of SEQ ID NO: 130; ar. nucleotides 34-825 of SEQ ID NO:127; as. nucleotides 11012-11412 of SEQ ID NO:135; at. nucleotides 3178-3786 of SEQ ID NO:134; au. nucleotides 143-518 of SEQ ID NO:140; av. nucleotides 17795-18116 of SEQ ID NO:130; aw. nucleotides 3388-3786 of SEQ ID NO: 134; ax. nucleotides 502-902 of SEQ ID NO: 126; ay. nucleotides 23737-24368 of SEQ ID NO:131; az. nucleotides 1805-2204 of SEQ ID NO:131; ba. nucleotides 5841-6441 of SEQ ID NO:135; bb. nucleotides 26613-27098 of SEQ ID NO:130; be. nucleotides 19968-20369 of SEQ ID NO: 138; bd. nucleotides 19636-21357 of SEQ ID NO:136; be. nucleotides 5881-6229 of SEQ ID NO:142; and bf. nucleotides 2440-2560 of SEQ ID NO: 134; or the complement of any of a-bf above;

wherein the SNP is associated with a muscle adverse effect in response to administration of the statin, thereby inferring the muscle adverse effect statin response of the subject.

2. The method of claim 1, wherein the SNP is located at: a. nucleotide 4332 of SEQ ID NO: 134; b. nucleotides 31683 of SEQ ID NO: 131; c. nucleotides 23077 of SEQ ID NO: 143; d. nucleotides 4208 of SEQ ID NO: 134; e. nucleotides of SEQ ID NO: 132; f. nucleotides 860 of SEQ ID NO: 131 ; g. nucleotides 971 of SEQ ID NO: 142; h. nucleotides 2098 of SEQ ID NO: 133; i. nucleotides 80160 SEQ ID NO: 131; j. nucleotides 2500 of SEQ ID NO: 134; k. nucleotides 23809 of SEQ ID NO: 131; 1. nucleotides 30635 of SEQ ID NO: 131; m. nucleotides 24272 of SEQ ID NO: 131; n. nucleotides 13780 of SEQ ID NO: 143; o. nucleotides 296935 of SEQ ID NO: 130; p. nucleotides 8462 of SEQ ID NO: 143; q . nucleotide 13665 of SEQ ID NO: 138; r. nucleotide 26256 of SEQ ID NO: 138; s. nucleotide 26137 of SEQ ID NO:138; t. nucleotide 17836 of SEQ ID NO: 138; u. nucleotide 25554 of SEQ ID NO: 138; v. nucleotide 12353 of SEQ ID NO: 138; w. nucleotide 7444 of SEQ ID NO:139; x. nucleotide 5832 of SEQ ID NO: 135; y. nucleotide 6063 of SEQ ID NO: 135; z. nucleotide 8004 of SEQ ID NO: 139; aa. nucleotide 860 of SEQ ID NO : 131 ;

ab. nucleotide 4550 of SEQ ID NO: 139; ac. nucleotide 3300 of SEQ ID NO: 139; ad. nucleotide 4208 of SEQ ID NO: 131 ; ae. nucleotide 4597 of SEQ ID NO: 139; af. nucleotide 31671 of SEQ ID NO: 131; ag. nucleotide 16399 of SEQ ID NO: 145; ah. nucleotide 2097 of SEQ ID NO: 145; ai. nucleotide 11987 of SEQ ID NO:139; aj. nucleotide 3500 of SEQ ID NO: 129; ak. nucleotide 30434 of SEQ ID NO: 131 ; al. nucleotide 930 of SEQ ID NO: 134; am. nucleotide 6046 of SEQ ID NO: 145; an. nucleotide 25286 of SEQ ID NO: 145; ao. nucleotide 18060 of SEQ ID NO: 130; ap. nucleotide 26950 of SEQ ID NO: 130; aq. nucleotide 26950 of SEQ ID NO: 130; ar. nucleotide 734 of SEQ ID NO: 127; as. nucleotide 11212 of SEQ ID NO:135; at. nucleotide 3671 of SEQ ID NO: 134; au. nucleotide 326 of SEQ ID NO: 140; av. nucleotide 18060 of SEQ ID NO: 130; aw. nucleotide 3671 of SEQ ID NO:134; ax. nucleotide 702 of SEQ ID NO: 126; ay. nucleotide 24205 of SEQ ID NO:131; az. nucleotide 2005 of SEQ ID NO:131; ba. nucleotide 6063 of SEQ ID NO: 135; bb. nucleotide 26806 of SEQ ID NO: 130; be. nucleotide 20169 of SEQ ID NO:138; bd. nucleotide 20343 of SEQ ID NO: 136; be. nucleotide 6183 of SEQ ID NO:142; or bf. nucleotide 2500 of SEQ ID NO: 134.

3. The method of claim 1 , comprising identifying a nucleotide occurrence of each of at least two statin response-related SNPs.